OTC · Financial Statements
Eupraxia Pharmaceuticals Inc. (EPRXF) Financial Statements
$3.04
OTC: EPRXF
Market Cap $108.29M
Overview Financials Dividend
Eupraxia Pharmaceuticals Inc. most recently reported annual revenue of $0, a net loss of $38.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2019 2020 2021 2022 2023
Revenue $0 $0 $0 $0 $0 Operating Profit $-6.0M $-2.0M $-21.0M $-23.0M $-38.0M Net Profit $-7.0M $-4.0M $-23.0M $-23.0M $-38.0M EPS $-0.56 $-0.31 $-1.61 $-1.21 $-1.58 Op Margin — — — — —
Balance Sheet (USD)
Metric 2019 2020 2021 2022 2023
Total Assets $3.0M $1.0M $31.0M $26.0M $27.0M Total Liabilities $21.0M $23.0M $12.0M $15.0M $26.0M Cash $1.0M $0 $21.0M $25.0M $26.0M Borrowings $12.0M $13.0M $10.0M $11.0M $14.0M
Cash Flow (USD)
Metric 2019 2020 2021 2022 2023
Operating Cash Flow $-5.0M $0 $-15.0M $-19.0M $-28.0M Investing Cash Flow $-2.0M $0 $-15.0M $8.0M $0 Financing Cash Flow $7.0M $-1.0M $50.0M $14.0M $21.0M Net Cash Flow $0 $-1.0M $21.0M $4.0M $1.0M Free Cash Flow $-5.0M $0 $-15.0M $-19.0M $-28.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.15 EV / EBITDA -3.94 FCF Yield -13.84% Quick Ratio 19.30 Interest Coverage -19.00 Return 1Y — Return 3Y — Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .